Public trial registry of the CCC-Munich

Trial ReBeL

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
ReBeL
World
Full title
:

A randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in Patients >18years with relapsed follicular lymphoma.

World
Description
:

A randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in Patients >18years with relapsed follicular lymphoma.

World
EudraCT number
:
World
Responsible organization
:
Medizinische Klinik III, Telefon: 089440072551
Indications
Classification Code Description
ICD-10-GM C82.- Follikuläres Lymphom
- Bloodcancer (leukemia, lymphoma)
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Open
World
Phase
:
I/II
Status
World
Status
:
Recruitment active
Votes
World
Institutional review board - vote
:
Unknown
Initiiation & lock
World
Date of lock (planned / actual)
:
2013-06-30 / Unknown
Therapy
World
Therapy line
:
2
Participants
Function Prename Surname Organization
World Principal Investigator MARTIN DREYLING Keine Organisationseinheit angegeben Magnifier